441 related articles for article (PubMed ID: 30499732)
1. Two year continuation rates of contraceptive methods in France: a cohort study from the French national health insurance database.
Agostini A; Godard C; Laurendeau C; Benmahmoud Zoubir A; Lafuma A; Lévy-Bachelot L; Gourmelen J; Linet T
Eur J Contracept Reprod Health Care; 2018 Dec; 23(6):421-426. PubMed ID: 30499732
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and cost of contraception in France (FACET study): a cohort study from the French National Healthcare Insurance Database.
Agostini A; Godard C; Laurendeau C; Benmahmoud A; Lafuma A; Doz M; Lévy-Bachelot L; Gourmelen J; Linet T
Eur J Obstet Gynecol Reprod Biol; 2018 Oct; 229():137-143. PubMed ID: 30176517
[TBL] [Abstract][Full Text] [Related]
3. Estimated disability-adjusted life years averted by long-term provision of long acting contraceptive methods in a Brazilian clinic.
Bahamondes L; Bottura BF; Bahamondes MV; Gonçalves MP; Correia VM; Espejo-Arce X; Sousa MH; Monteiro I; Fernandes A
Hum Reprod; 2014 Oct; 29(10):2163-70. PubMed ID: 25085802
[TBL] [Abstract][Full Text] [Related]
4. A randomized clinical trial of the effect of intensive versus non-intensive counselling on discontinuation rates due to bleeding disturbances of three long-acting reversible contraceptives.
Modesto W; Bahamondes MV; Bahamondes L
Hum Reprod; 2014 Jul; 29(7):1393-9. PubMed ID: 24812309
[TBL] [Abstract][Full Text] [Related]
5. Initiation and continuation of long-acting reversible contraception in the United States military healthcare system.
Chiles DP; Roberts TA; Klein DA
Am J Obstet Gynecol; 2016 Sep; 215(3):328.e1-9. PubMed ID: 27005514
[TBL] [Abstract][Full Text] [Related]
6. A systematic review on clinical effectiveness, side-effect profile and meta-analysis on continuation rate of etonogestrel contraceptive implant.
Moray KV; Chaurasia H; Sachin O; Joshi B
Reprod Health; 2021 Jan; 18(1):4. PubMed ID: 33407632
[TBL] [Abstract][Full Text] [Related]
7. Acceptability of long-acting, progestin-only contraception in Europe: a two-year prospective, non-interventional study.
Short M; Dallay D; Omokanye S; Stauch K; Inki P
Eur J Contracept Reprod Health Care; 2014 Feb; 19(1):29-38. PubMed ID: 24289528
[TBL] [Abstract][Full Text] [Related]
8. Long-acting reversible contraceptive acceptability and unintended pregnancy among women presenting for short-acting methods: a randomized patient preference trial.
Hubacher D; Spector H; Monteith C; Chen PL; Hart C
Am J Obstet Gynecol; 2017 Feb; 216(2):101-109. PubMed ID: 27662799
[TBL] [Abstract][Full Text] [Related]
9. Intrauterine device continuation rates and reasons for discontinuation in a Central European clinic with a high standard of care and ultrasound follow-up: a retrospective cohort study.
Bachofner M; Blickenstorfer K; Hutmacher J; Wehrle L; Leeners B; Merki-Feld G
Eur J Contracept Reprod Health Care; 2018 Dec; 23(6):407-414. PubMed ID: 30628516
[TBL] [Abstract][Full Text] [Related]
10. Immediate postabortion initiation of levonorgestrel implants reduces the incidence of births and abortions at 2 years and beyond.
Rose SB; Garrett SM; Stanley J
Contraception; 2015 Jul; 92(1):17-25. PubMed ID: 25818594
[TBL] [Abstract][Full Text] [Related]
11. Reasons for Brazilian women to switch from different contraceptives to long-acting reversible contraceptives.
Ferreira JM; Nunes FR; Modesto W; Gonçalves MP; Bahamondes L
Contraception; 2014 Jan; 89(1):17-21. PubMed ID: 24156884
[TBL] [Abstract][Full Text] [Related]
12. Three-year continuation of reversible contraception.
Diedrich JT; Zhao Q; Madden T; Secura GM; Peipert JF
Am J Obstet Gynecol; 2015 Nov; 213(5):662.e1-8. PubMed ID: 26259905
[TBL] [Abstract][Full Text] [Related]
13. Extended use up to 5 years of the etonogestrel-releasing subdermal contraceptive implant: comparison to levonorgestrel-releasing subdermal implant.
Ali M; Akin A; Bahamondes L; Brache V; Habib N; Landoulsi S; Hubacher D;
Hum Reprod; 2016 Nov; 31(11):2491-2498. PubMed ID: 27671673
[TBL] [Abstract][Full Text] [Related]
14. Temporal Trends in the Uptake and Continuation of the Etonogestrel Implant in a Large Private Practice Setting.
Howard DL; Ford A; Ceballos S; Volker KW
J Womens Health (Larchmt); 2018 Feb; 27(2):191-195. PubMed ID: 28976797
[TBL] [Abstract][Full Text] [Related]
15. Experiences with the levonorgestrel-releasing intrauterine system in Kenya: qualitative interviews with users and their partners.
Nanda G; Rademacher K; Solomon M; Mercer S; Wawire J; Ngahu R
Eur J Contracept Reprod Health Care; 2018 Aug; 23(4):303-308. PubMed ID: 30198796
[TBL] [Abstract][Full Text] [Related]
16. Complications and continuation rates associated with 2 types of long-acting contraception.
Berenson AB; Tan A; Hirth JM
Am J Obstet Gynecol; 2015 Jun; 212(6):761.e1-8. PubMed ID: 25555662
[TBL] [Abstract][Full Text] [Related]
17. Intrauterine Contraception Continuation in Adolescents and Young Women: A Systematic Review.
Usinger KM; Gola SB; Weis M; Smaldone A
J Pediatr Adolesc Gynecol; 2016 Dec; 29(6):659-667. PubMed ID: 27386754
[TBL] [Abstract][Full Text] [Related]
18. The levonorgestrel intrauterine system: cohort study to assess satisfaction in a postpartum population in Kenya.
Hubacher D; Masaba R; Manduku CK; Chen M; Veena V
Contraception; 2015 Apr; 91(4):295-300. PubMed ID: 25601351
[TBL] [Abstract][Full Text] [Related]
19. Free-of-charge long-acting reversible contraception: two-year discontinuation, its risk factors, and reasons.
Saloranta TH; Gyllenberg FK; But A; Gissler M; Laine MK; Heikinheimo O
Am J Obstet Gynecol; 2020 Dec; 223(6):886.e1-886.e17. PubMed ID: 32562657
[TBL] [Abstract][Full Text] [Related]
20. Choice of the levonorgestrel intrauterine device, etonogestrel implant or depot medroxyprogesterone acetate for contraception after aspiration abortion.
Steinauer JE; Upadhyay UD; Sokoloff A; Harper CC; Diedrich JT; Drey EA
Contraception; 2015 Dec; 92(6):553-9. PubMed ID: 26093190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
